Jantoven website quotation

[Guest guest]

Below is a short quote from Jantoven site. Interesting to me they are located

in Minnesota, where so much heart-device research & manufacturing is done.

Upsher claims it is cheaper than Coumadin. It is warfarin sodium.

Hope this ads to knowledge of this new competitor.

LJ

JANTOVEN® offers an exciting option in anticoagulation therapy

The first generic warfarin sodium to be offered with brand-name support

Effective and economical

Reduces the risk of thromboembolic events, myocardial infarction, and stroke

Prescribe JANTOVEN® and be assured your patients will receive:

Precise, effective anticoagulation dose to dose and day to day

Therapeutic equivalence to Coumadin®* (warfarin sodium tablets, USP)1

Affordable pricing and co-pays

A drug they can trust for both the short term and the long term

Switch your current warfarin sodium patients with confidence†

Safe and effective

Considerable savings over Coumadin®*

AB-rating, which smoothes the way for formulary inclusion

Important Safety Information

The most common and serious risks of oral anticoagulant therapy are bleeding in

any tissue or organ and, less frequently (<0.1%), necrosis and/or gangrene of

skin and other tissues.

Appropriate monitoring is essential when dosage is initiated, changed, or other

medications are coadministered. Numerous factors, alone or in combination, may

influence a patient’s response to JANTOVEN® (warfarin sodium tablets, USP),

including travel, changes in diet, environment, physical state, and other

medications. The incidence of major bleeding in clinical studies of atrial

fibrillation patients ranged from 0.6% to 2.7%.

JANTOVEN® is contraindicated in situations including:

Where the risk of hemorrhage is greater than the potential clinical benefit of

therapy or actual hemorrhage has occurred Pregnancy (Category X) Alcoholism

Unsupervised senility/psychosis

Full Prescribing Information (.pdf).

*Coumadin® is a registered trademark of Bristol-Myers Squibb Company. †U.S.

Food and Drug Administration position statement: “Additional clinical tests or

examinations by the health care provider are not needed when a generic drug

product is substituted for the brand-name product.”2

References

Data on file, Upsher- Laboratories, Inc. Nightingale SL. Therapeutic

equivalence of generic drugs: letter to health practitioners. January 28, 1998.

Available at: http://www.fda.gov/cder/news/nightgenlett.htm. Accessed April 25,

2003